TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02966249
Drug: Dexmetomidine intravenously
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of dexdemetomidine at a rate of 0.25 μg/kg/h given intravenously 10 min before spinal anesthesia in total knee arthroplasty
Study: NCT02966249
Drug: Ringer's Lactate solution intravenously
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of Ringer's Lactate solution given intravenously, starting 10 minutes before spinal anesthesia up to the end of the operation
Study: NCT02966249
Drug: Dexmetomidine intrathecally
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 μgr dexmetomidine given intrathecally once for anesthesia in total knee replacement
Study: NCT02613403
Drug: MK-3682B
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two MK- 3682B 1,136 mg FDC tablets each containing 50 mg MK-5172 (GZR), 225 mg MK-3682 (UPR, formerly IDX21437), and 30 mg MK-8408 (RZR) taken once daily by mouth.
Study: NCT02244463
Drug: MLN0128
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03420781
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injected twice daily
Study: NCT00411242
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04481789
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tablets
Study: NCT03775902
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo tablet
Study: NCT03382834
Drug: Antiretroviral drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive antiretroviral drugs provided by their own doctors. Antiretroviral drugs will not be provided by the study.
Study: NCT03220295
Drug: Placebo Dose Escalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: dose levels of the cohorts will be increased step wise
Study: NCT04000438
Drug: DF01
Normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The subject receives sc injections of tafoxiparin solution once daily for up to 7 days until labor induction or spontaneous onset of labor. Induction is done according to clinical practice; 1st balloon, 2nd PGE1
Study: NCT05148169
Drug: SSRIs
Approvals — FDA: no, EMA: no, PMDA: no
Description: One SSRI(No-specified) is prescribed based on treatment guidelines for major depressive disorder and drug prescription manual. The dose is 20-60mg/day for fluoxetine, 20-40mg/day for paroxetine, 100-300mg/day for fluvoxamine, 50-200mg/day for sertraline, 20-40mg/day for citalopram, 10-20mg/day for escitalopram, respectively.
Study: NCT01860300
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00426608
Drug: GSK561679
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK561679 tablets will be available with dose strength of 50, 10 and 200 mg.
Study: NCT04317508
Drug: Benzocaine oral gel 20%
Approvals — FDA: no, EMA: no, PMDA: no
Description: control group
Study: NCT01762202
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02235077
Drug: Spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients receiving no MRA at home will receive spironolactone 100 mg (4x25 mg capsules) once daily for 96 hours.~Patients already receiving low-dose MRA at home will be randomized to receive spironolactone 25 mg (1x25 mg capsules) or 100 mg (4x25 mg capsules) in hospital for 96 hours. The patients who are randomized to 25 mg spironolactone will also receive 75 mg placebo (3x25 mg capsules) in order to maintain blinding.
Study: NCT02235077
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receiving no MRA at home will receive 100 mg placebo (4x25 mg capsules) once daily for 96 hours.~Patients who are randomized to 25 mg spironolactone will also receive 75 mg placebo (3x25 mg capsules) in order to maintain blinding.
Study: NCT01042184
Drug: Sequential therapy for 14 days
Approvals — FDA: no, EMA: no, PMDA: no
Description: D1-D7: (lansoprazole 30mg + amoxicillin 1gm) bid D8-D14: (lansoprazole 30mg + clarithromycin 500mg + metronidazole 500mg) bi
Study: NCT01042184
Drug: Sequential therapy for 10 days
Approvals — FDA: no, EMA: no, PMDA: no
Description: D1-D5: (lansoprazole 30mg + amoxicillin 1gm) bid D6-D10: (lansoprazole 30mg+clarithromycin 500mg+metronidazole 500mg) bid
Study: NCT01042184
Drug: Triple therapy for 14 days
Approvals — FDA: no, EMA: no, PMDA: no
Description: D1-D14: (lansoprazole 30mg + clarithromycin 500mg + amoxicillin 1gm) bid
Study: NCT00338598
Drug: Glycine
Normalized name: Glycine
DrugBank: Glycine (DB00145)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glycine, 0.8 gr per kg given in two daily doses
Study: NCT00338598
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01127646
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally, once daily for random nonconsecutive 6 days during 4-week treatment period.
Study: NCT01129388
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: matching tablet~Route of administration: oral
Study: NCT02858999
Drug: PAD-VCD
Normalized name: STATLOCK PICC,VCDC ANCHOR DEVICE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 weeks of induction chemotherapy by liposomal Bortezomib-Dexamethasone-Doxorubicin (PAD) alternating with Bortezomib-Dexamethasone-Cyclophosphamide (VCD) for a total of 4 cycles
Study: NCT00969397
Drug: Topical Antiangiogenic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Antiangiogenic
Study: NCT03799692
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: Nanoparticle Albumin-Bound Paclitaxel Nanoparticle Albumin-Bound Paclitaxel 125mg/m2, iv, d1, 8, 15.~Drug: Carboplatin AUC=2 iv, d1, 8, 15.
Study: NCT02313909
Drug: Acetylsalicylic acid (Aspirin, BAY1019036)
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg, once daily, orally, tablet
Study: NCT00169559
Drug: GW590735
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1µg to 20µg daily doses of GW590735
Study: NCT02054767
Drug: Intervention: inferior alveolar nerve block injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: -22 patients received inferior alveolar nerve block injections of 3.6 mL (equivalent to 2 cartridges)
Study: NCT03492762
Drug: Cu-DOTA-ECL1i
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiolabeled probe called Cu-DOTA-ECL1i that recognizes CCR2 and propose to image CCR2 in the lung to ultimately guide diagnosis and therapy.
Study: NCT02176577
Drug: Product 0405
Normalized name: Pyelocalyceal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Product 0405 will be administered topically, twice daily for 28 days.
Study: NCT04057261
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo once daily, subcutaneous injection via pre-filled pen.
Study: NCT03794076
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline nasal spray will be administered intranasally (nasal spray) (1 spray each nostril 4 times a day, 5.2 mg/spray)
Study: NCT01217099
Drug: azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: control patients were iv azithromycin for 5 days.
Study: NCT00738400
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo tablets daily for 4 weeks, placebo tablets daily for consecutive 4 weeks
Study: NCT02698657
Drug: ASP5094
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV)
Study: NCT01046058
Drug: TMC435
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg (two 75-mg capsules) orally (by mouth) once daily for 7 days
Study: NCT01062113
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Initial dose: Celecoxib 200mg tablet x 2 will be administrated during a period from 1 to 2 hours post lateral mandibular impacted third molar tooth extraction in subjects with moderate pain or severe painrated as 45.0 mm or more on the VAS
Study: NCT01062113
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Additional dose: Celecoxib 200mg tablet x 1 will be administrated during a period from 5 to 12 hours post-initial dose of Celecoxib 400mg in subjects who require an additional analgesic dose for any pain
Study: NCT01062113
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Additional dose: Placebo (tablet) will be administrated during a period from 5 to 12 hours post-initial dose of Celecoxib 400mg in subjects who require an additional analgesic dose for any pain
Study: NCT00661609
Drug: AZD4877
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV)25mg/weekly
Study: NCT02826200
Drug: Acenocoumarol
Normalized name: acenocoumarol
DrugBank: Acenocoumarol (DB01418)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care plus oral anticoagulant therapy (acenocoumarol)
Study: NCT01430403
Drug: Inhaled Corticosteroid Boost Therapy (ICS)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-administered fluticasone (Flovent ® Diskus®) inhalers sufficient to deliver the required 200 mcg or 500 mcg daily boost of fluticasone. All participants will receive standardized specialist asthma care.
Study: NCT00247650
Drug: Zoledronic Acid; Letrozole
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00509834
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT03079011
Drug: Aromatase Inhibitors
Normalized name: Aromatase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole: 2.5 mg once daily on a continuous scheme (tablets, per os) Anastrozole:1 mg once daily on a continuous scheme (tablets , per os) Exemestane: 25 mg once daily on a continuous scheme (tablets, per os)
Study: NCT00325364
Drug: Human Insulin Inhalation Powder
Normalized name: insulin, regular, human Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: patient specific dose, inhaled, before meals, 24 months
Study: NCT02787707
Drug: Persumac
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.7 grams Persumac powder (Iranian traditional medicine remedy composed from sumac and Bunium Persicum) every 8 hour
Study: NCT02787707
Drug: lactose
Normalized name: Lactose
DrugBank: Lactose (DB04465)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.7 grams Lactose every 8 hour
Study: NCT02067884
Drug: Definity, (Lipid Microspheres) Intravenous Suspension
Normalized name: Definity, (lipid microspheres) intravenous suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participant will receive contrast agent by intravenous administration
Study: NCT00995501
Drug: anesthesia management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Light anesthesia to maintain BIS about 55
Study: NCT04590586
Drug: Standard of care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care (SoC) treatment for COVID-19 infection in line with institutional practice. The SoC may change as new information becomes available about treating COVID-19.
Study: NCT02007434
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phosphate buffered saline placebo for injection
Study: NCT02007434
Drug: Lidocaine / Epinephrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 4% topical cream applied 45 minutes prior to dosing across the area to be treated, followed by 0.4 mL SC injections of lidocaine HCl 1% / epinephrine 1:100,000 around the perimeter of the treatment area and across the treatment area in a regular pattern 25 minutes before dosing.
Study: NCT02007434
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen 600 mg at least 1 hour prior to dosing and 600 mg 3 times a day for at least 3 days after dosing.
Study: NCT00855062
Drug: minocycline
Normalized name: Minocycline
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg capsule every 12 hours by mouth
Study: NCT00855062
Drug: minocycline placebo capsule
Normalized name: minocycline Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 capsule every 12 hours by mouth
Study: NCT01013610
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escalating dose
Study: NCT00929162
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo for ZD4054 10 mg
Study: NCT01355458
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: applied topically once daily
Study: NCT01320332
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablets
Study: NCT00868465
Drug: Artemether-Lumefantrine
Normalized name: artemether-lumefantrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with artemether-lumefantrine (AL; Coartem; Novartis Pharma), administered as half a tablet (20 mg of artemether and 120 mg of lumefantrine) per 5 kg of body weight in a 6-dose regimen (at enrolment and 8, 20, 32, 44, and 56 h \[+/-90 min\] after the initiation of treatment). AL is currently the first line treatment in Tanzania
Study: NCT01376323
Drug: GSK256073 1mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK256073 1mg capsule
Study: NCT01376323
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo capsule
Study: NCT03406546
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Remifentanil was used to prevent cough induced by bronchoscopy.
Study: NCT01135017
Drug: Placebo (for Dronedarone)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Film-coated tablet strictly identical in appearance~Oral administration under fed conditions (during breakfast and dinner)
Study: NCT01694732
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01269996
Drug: Janumet, Lantus
Approvals — FDA: no, EMA: no, PMDA: no
Description: In this multicentre, randomized, open-label prospective study. Recruited patients will be randomized to one of the two treatment groups. Treatment efficacy and safety in terms of HbA1c control and hypoglycemic events will be evaluated.~Treatment groups:~Group 1 - Metformin followed by Sulfonylurea (Gliclazide) and supplementary intermediate-acting insulin (Protaphane) injection.~Group 2 - Janumet followed by Lantus insulin injection.
Study: NCT01155154
Drug: clindamycin
Normalized name: Clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 300 mg of clindamycin (two 150 mg capsules) every 6 hours for 7 days
Study: NCT01155154
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two placebo capsules every 6 hours for 7 days
Study: NCT01475851
Drug: GSK548470 300 mg tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blue tablets containing 300 mg of tenofovir disoproxil fumarate
Study: NCT00002641
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002641
Drug: isolated perfusion
Normalized name: ISOLATE
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01242202
Drug: alpha glucosidase inhibitor
Normalized name: Alpha glucosidase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT01497522
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo of vildagliptin 50 mg twice daily
Study: NCT02110901
Drug: PRT-201
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02110901
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01744379
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00637000
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo soluble film administered on the same schedule as active treatment to maintain the study blind.
Study: NCT01290679
Drug: TMC435
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg capsule once daily for 12 weeks in addition to peginterferon alfa-2a or peginterferon alfa-2b and ribavirin for 24 or 48 weeks
Study: NCT04681911
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine, 1000 mg/m2, d1-d14, 3-week cycle
Study: NCT00623740
Drug: hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous slow of hemisuccinate hydrocortisone 0.5 mg/kg/12 hours during 7 days then 0.5mg/kg/24 hours during 3 days.
Study: NCT03098199
Drug: 150IU Menopur
Approvals — FDA: no, EMA: no, PMDA: no
Description: \<1.5 AMH group
Study: NCT03098199
Drug: 225IU Gonal-F
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.6-2.5 AMH group
Study: NCT03098199
Drug: 75IU Menopur
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.6-2.5 AMH group 2.6-6.9 AMH group \>7.0 AMH group
Study: NCT03467932
Drug: Cohort A: ORMD-0801
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part 1 In the first two weeks of active treatment (Part 1) subjects will receive double-blind therapy according to their randomized regimen (placebo or ORMD-0801) to be taken QHS, BID or TID. Subjects will undergo a step-wise dose escalation from a starting dose of 16 mg (Visit 3), to 24 mg (Visit 4), to a top dose of 32 mg (Visit 5 onward). Subjects will then enter Part 2.~Part 2:~During Part 2, subjects will remain on fixed doses of ORMD-0801 (or matched placebo) for 10 weeks. Doses will not be adjusted unless clinically indicated for adverse events or hypoglycemia.
Study: NCT03467932
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo provided QHS, BID, TID
Study: NCT03098199
Drug: 150IU Gonal-F
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.6-6.9 AMH group
Study: NCT03098199
Drug: 75IU Gonal-F
Approvals — FDA: no, EMA: no, PMDA: no
Description: \>7.0 AMH group
Study: NCT03467932
Drug: Cohort B: ORMD-0801
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part 1 In the first two weeks of active treatment, subjects will receive double-blind therapy according to their randomized regimen (ORMD 0801 8 mg or 16 mg, or matched placebo) to be taken QHS or BID. Subjects will then enter Part 2 at the same dose and regimen administered in Part 1.~Part 2 Subjects will remain on fixed doses of ORMD-0801 (or matched placebo) for 10 weeks. Doses will not be adjusted unless clinically indicated for adverse events or hypoglycemia.
Study: NCT03804710
Drug: Developmental moisturizing cream 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will topically apply developmental moisturizing cream 1
Study: NCT03804710
Drug: Developmental moisturizing cream 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will topically apply developmental moisturizing cream 2
Study: NCT02557581
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02614742
Drug: SFX-01
Approvals — FDA: no, EMA: no, PMDA: no
Description: An intervention releasing sulforaphane.
Study: NCT03036865
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose administered IV or SC
Study: NCT01661972
Drug: Capecitabine and aflibercept
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine given on days 1-14 and off days 15-21. Dose: Phase 1 cohort 1 850mg/m2 Phase 1 cohort 2 1000mg/m2, Phase 2 RPTD.~Aflibercept will be held constant at 6 mg/kg, given intravenously every 3 weeks.~Both agents will be administered on a 21-day cycle.
Study: NCT00667732
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5mcg twice a day, increased to 10mcg twice a day for 24 weeks
Study: NCT01094106
Drug: NaCl 0,9%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative wound infusion 2 ml/h/48h
Study: NCT01292551
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets 2 x daily for 2 weeks, then change to different placebo tablets to match Bosentan group, 2 x daily for 12 weeks
Study: NCT01602406
Drug: LJM716
Approvals — FDA: no, EMA: no, PMDA: no
Description: LJM716
Study: NCT02034708
Drug: Dotarem®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dotarem® 0.1 mmoL/kg (0.2 mL/kg), intravenous (I.V.) bolus.
Study: NCT02034708
Drug: Gadovist®/Gadavist®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gadovist®/Gadavist®, 0.1mmol/kg (0.1mL/kg), intravenous (I.V.) bolus.
Study: NCT00543595
Drug: MK0916
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04392063
Drug: Melatonin 3 mg
Normalized name: melatonin 3 MG
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The children received crushed Melatonin 3-mg tablets daily, 30-minutes before bedtime for 3-months.
Study: NCT03831321
Drug: Diclofenac Sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 50 mg of diclofenac sodium will be administered to intervention group one hour before cystoscopy and lubricant gel with lidocaine will be administered to all patients just before cystoscopy.
Study: NCT03831321
Drug: Lubricant Gel
Normalized name: Surgilube Lubricant Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: To prevent patients from side effects of cystoscopy ( like urethral strictures and discomfort)
Study: NCT02725372
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part 1 Placebo arm: Inhaled Nitric Oxide 15mcg/Kg IBW/hrfor two week run in period dose titrated to Inhaled Nitric Oxide 75 mcg/kg IBW/hr at randomizationTreatment Period
Study: NCT00529490
Drug: Hypertonic lactate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral solution administered to a maximal volume of 10 ml/kg BW over the first 12 hours post-CABG
Study: NCT00529490
Drug: Ringer's lactate
Normalized name: Ringer's lactate/gel dressing 2.2" TOPICAL KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral solution administered to a maximal dose of 30 ml/kg BW over the first 12 hours post-CABG
Study: NCT01774864
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01746095
Drug: Placebo inhalation powder
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03315143
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo was administered as a tablet(s) (identical to the sotagliflozin tablet in appearance), orally once daily.
Study: NCT00181571
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: up to a maximum dose of 1.3 mg Placebo /kg/day, and not more than 144 mg/day for any subject regardless of weight.
Study: NCT00335452
Drug: acetylsalicyclic acid (ASA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administration
Study: NCT03554174
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: microcrystalline cellulose capsule